377 related articles for article (PubMed ID: 26391102)
1. Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients?
van la Parra RF; de Wilt JH; Mol SJ; Mulder AH; de Roos WK; Bosscha K
Breast J; 2015; 21(6):621-6. PubMed ID: 26391102
[TBL] [Abstract][Full Text] [Related]
2. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study.
Delpech Y; Bricou A; Lousquy R; Hudry D; Jankowski C; Willecocq C; Thoury A; Loustalot C; Coutant C; Barranger E
Ann Surg Oncol; 2013 Aug; 20(8):2556-61. PubMed ID: 23456432
[TBL] [Abstract][Full Text] [Related]
3. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
4. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
5. Size of Extranodal Extension on Sentinel Lymph Node Dissection in the American College of Surgeons Oncology Group Z0011 Trial Era.
Choi AH; Blount S; Perez MN; Chavez de Paz CE; Rodriguez SA; Surrusco M; Garberoglio CA; Lum SS; Senthil M
JAMA Surg; 2015 Dec; 150(12):1141-8. PubMed ID: 26331347
[TBL] [Abstract][Full Text] [Related]
6. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
[TBL] [Abstract][Full Text] [Related]
7. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
8. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
9. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
[TBL] [Abstract][Full Text] [Related]
10. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.
Morrow M; Van Zee KJ; Patil S; Petruolo O; Mamtani A; Barrio AV; Capko D; El-Tamer M; Gemignani ML; Heerdt AS; Kirstein L; Pilewskie M; Plitas G; Sacchini VS; Sclafani LM; Ho A; Cody HS
Ann Surg; 2017 Sep; 266(3):457-462. PubMed ID: 28650355
[TBL] [Abstract][Full Text] [Related]
11. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
[TBL] [Abstract][Full Text] [Related]
12. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
13. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
14. When is a completion axillary lymph node dissection necessary in the presence of a positive sentinel lymph node?
Suyoi A; Bains SK; Kothari A; Douek M; Agbaje O; Hamed H; Fentiman I; Pinder S; Purushotham AD
Eur J Cancer; 2014 Mar; 50(4):690-7. PubMed ID: 24331957
[TBL] [Abstract][Full Text] [Related]
15. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
[TBL] [Abstract][Full Text] [Related]
16. Axillary node staging for microinvasive breast cancer: is it justified?
Lyons JM; Stempel M; Van Zee KJ; Cody HS
Ann Surg Oncol; 2012 Oct; 19(11):3416-21. PubMed ID: 22576061
[TBL] [Abstract][Full Text] [Related]
17. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection.
Hwang RF; Gonzalez-Angulo AM; Yi M; Buchholz TA; Meric-Bernstam F; Kuerer HM; Babiera GV; Tereffe W; Liu DD; Hunt KK
Cancer; 2007 Aug; 110(4):723-30. PubMed ID: 17587208
[TBL] [Abstract][Full Text] [Related]
18. Predictors of non-sentinel lymph node metastasis in breast cancer patients.
Goyal A; Douglas-Jones A; Newcombe RG; Mansel RE;
Eur J Cancer; 2004 Jul; 40(11):1731-7. PubMed ID: 15251163
[TBL] [Abstract][Full Text] [Related]
19. The Importance of Applying ACOSOG Z0011 Criteria in the Axillary Management of Invasive Lobular Carcinoma: A Multi-institutional Cohort Study.
Roberts A; Nofech-Mozes S; Youngson B; McCready DR; Al-Assi M; Ramkumar S; Cil T
Ann Surg Oncol; 2015 Oct; 22(10):3397-401. PubMed ID: 26215196
[TBL] [Abstract][Full Text] [Related]
20. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.
Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB
Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
